Kyivstar’s $160 Million Move: Tabletki.ua Deal Bolsters Ukraine’s Digital Healthcare Access

Acquisition Integrates Ukraine’s Largest Digital Pharmacy Platform Into Kyivstar’s Expanding Portfolio

Kyivstar, Ukraine’s leading digital operator and a Nasdaq-listed company, just made a strategic leap in digital health. The company announced the acquisition of Tabletki.ua, Ukraine’s most popular medicine reservation platform, for $160 million. This deal is not just another acquisition; it immediately deepens Kyivstar’s impact on essential healthcare access for millions across Ukraine.

Backed by parent company VEON, Kyivstar is becoming a formidable digital ecosystem, extending beyond telecom and into everyday services from ride-hailing to digital TV—and, most recently, into e-health. Tabletki.ua already partners with over 14,000 pharmacies nationwide and enabled an average of 14 million monthly reservations in 2025, emphasizing its daily relevance to Ukrainian households.

In raw numbers, Tabletki.ua processed bookings with a gross merchandise value of UAH 45 billion (USD 1.06 billion) in FY2024, and UAH 57.3 billion (USD 1.19 billion) in the year ending September 2025, reflecting robust growth. It will join Kyivstar’s ambitious digital services lineup, further supported by earlier acquisitions like Helsi and strategic investments in platforms such as Uklon and Kyivstar TV.

Financials Reflect a Strong Growth Trajectory

With Tabletki.ua’s LTM net profit of $20 million and EBITDA of $24 million, the implied acquisition multiple stands at 8x earnings. For context, that’s a competitive valuation for a highly integrated digital health service with a broad national footprint.

Strategic Rationale: Strengthening a Digital Healthcare Ecosystem

This acquisition advances Kyivstar’s ambition to create Ukraine’s go-to digital services provider—and specifically, the leading platform for digital healthcare. By combining Kyivstar’s expertise in scaling technology and Tabletki.ua’s market dominance, the company aims to make healthcare simpler, more affordable, and more accessible for millions of Ukrainians.

Kyivstar isn’t new to digital health. Its 2022 acquisition of Helsi laid the groundwork, and the latest acquisition signals confidence in the long-term potential of Ukraine’s e-health sector amid ongoing digital transformation. For users, it means reliable pharmacy access, transparent pricing, and ease of medicine reservation across the nation.

Investor and Market Context: Expansion Amid Broader Digital Push

The acquisition comes as Kyivstar and VEON reaffirm a $1 billion multi-year investment plan for Ukraine, spanning infrastructure, tech upgrades, and strategic M&A. With a Nasdaq listing (tickers: KYIV, KYIVW) and an expanding portfolio, Kyivstar continues to attract attention from global investors interested in emerging market digitization themes.

Moreover, the transaction aligns with VEON’s wider push to leverage digital services in high-growth markets, capitalizing on economic shifts toward online access, remote healthcare, and nationwide resilience—especially relevant for Ukraine’s evolving tech and healthcare landscape.

Key Takeaway: Tabletki.ua Strengthens Kyivstar’s Health Leadership

Kyivstar’s acquisition of Tabletki.ua signals more than just market consolidation. It is a bet on digital-first healthcare for Ukraine, offering scale, innovation, and convenience at a critical time for the country’s recovery and modernization. Investors and observers alike will be watching how Kyivstar integrates and grows this high-traffic platform—and whether it sets a new benchmark for digital innovation across the region.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI